Prolactin may be a promising therapeutic target for myasthenia gravis: Hypothesis and importance
- 31 December 2008
- journal article
- Published by Elsevier BV in Medical Hypotheses
- Vol. 70 (5), 1017-1020
- https://doi.org/10.1016/j.mehy.2007.06.044
Abstract
No abstract availableKeywords
This publication has 36 references indexed in Scilit:
- Myasthenia gravis: past, present, and futureJCI Insight, 2006
- Prolactin synthesis by lymphocytes from patients with systemic sclerosisBiomedicine & Pharmacotherapy, 2006
- Estrogen Enhances Susceptibility to Experimental Autoimmune Myasthenia Gravis by Promoting Type 1-Polarized Immune ResponsesThe Journal of Immunology, 2005
- The Susceptibility to Experimental Myasthenia Gravis of STAT6−/− and STAT4−/− BALB/c Mice Suggests a Pathogenic Role of Th1 CellsThe Journal of Immunology, 2004
- Prolactin Suppresses Glucocorticoid-Induced Thymocyte Apoptosis in VivoEndocrinology, 2003
- “Crisis” in myasthenia gravis: An historical perspectiveMuscle & Nerve, 2002
- Prolactin (PRL) and Its Receptor: Actions, Signal Transduction Pathways and Phenotypes Observed in PRL Receptor Knockout MiceEndocrine Reviews, 1998
- New aspects of prolactin and immunity: a lymphocyte-derived prolactin-like product and nuclear protein kinase C activationTrends in Pharmacological Sciences, 1989
- Human T-helper lymphocytes in myasthenia gravis recognize the nicotinic receptor alpha subunit.Proceedings of the National Academy of Sciences of the United States of America, 1987
- The effect of hypophysectomy upon the involution of the thymus in the ratThe Anatomical Record, 1930